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Case Report
Systemic lupus during pregnancy with refractory alveolar
haemorrhage: recovery following termination of pregnancy
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A case of refractory pulmonary hemorrhage in a pregnant 22-year-old with systemic lupus is
presented. The clinical difficulty of management of pulmonary haemorrhage and lupus flare during
pregnancy are discussed.
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Case report
A 22-year-old female was diagnosed with SLE having
presented with arthralgia, oral ulcers and a malar rash.
She had a history of Raynaud’s disease since the age
of 12 years. ANA was positive at 1:640, anti-DNA
antibodies were positive at 286Iu/ml, ESR was 16.
She was commenced on hydroxychloroquine with
improvement of her rash but not her joint pain.
She was admitted 14 months later complaining of
dyspnoea and pleuritic chest pain. She had no
haemoptysis. Chest radiographs (CXR) revealed
diffuse alveolar infiltrates. Laboratory investigations
showed haemoglobin of 9.4 g/dl, pH 7.44, p02
50 mmHg, p02 25 mmHg, saturation 86% on room
air. Pulmonary function obtained on admission
showed FEV, 2.73 (87% predicted), FVC 3.00 (83%
predicted), DLCO was 145% predicted. She was noted
to have 3 + proteinuria and was 21 weeks pregnant.
Bronchoscopy revealed grossly blood stained lavage
and many haemosiderin laden macrophages. No
infectious pathogens were found despite an aggressive
search. A diagnosis of diffuse alveolar haemorrhage
was made and pulse methylprednisone was started
(500 mg daily for 3 days). She improved with this
treatment and azothioprine was added 4 days later.
Six days later she had recurrence of her symptoms
with a fall in her haemoglobin to 6.9 g/dl. She was
transferred to the University of Michigan where a
blood gas revealed pH 7.47, p02 67 mmHg, pC02
30 mmHg, saturation 92% on 100% face mask. She
was intubated and placed on mechanical ventilation.
CXR revealed diffuse infiltrates (Figure 1). The 24-h
urine collection revealed 2.7 g protein. BUN was
18mg/dl with a serum creatinine 0.3 mg/dl. The
ANA was positive 1:2560, and antibodies to double-
stranded DNA were minimally elevated by the Farr
assay at 11 (range 0-7). The patient did not have IgG
or IgM anticardiolipin antibodies, and had negative
tests for antibodies to RNP, Sm, Ro and La. The
VDRL was negative and the partial thromboplastin
time was 20.6 (normal 22.8-29.1 s). Because of
the life threatening nature of her illness, she was
commenced on once pulse of cyclophosphamide
0.5 g/M2 and methylprednisilone 1 g every day for 3
days. Plasmapheresis was also started 4 L/day for 4
days. Over the next few days she improved and was
extubated after 9 days of mechanical ventilation. She
continued to improve, with associated radiographic
clearing (Figure 2), until 8 days later when she
became confused with features of acute psychosis.
Magnetic resonance imaging of the brain did not show
any evidence of lupus cerebritis and spinal tap
revealed normal CSF. A presumptive diagnosis of
steroid psychosis was made and her prednisone was
reduced to 30 mg daily.
Eight days later her pulmonary haemorrhage
recurred with diffuse infiltrates on CXR (Figure 3)
and a fall in haemoglobin to 7.3 g/dl. Platelets at that
time were 89 000/mm.’ She was again intubated. Two
days later her platelet count had fallen to 45 000/mm’
and her bilirubin was increased at 2.6 mg/dl, hemo-
globin was stable at 9.0 g/dl. At the time of admission
the clinical presentation was not suggestive of pre-
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Figure 1 Chest radiograph following intubation showing diffuse
infiltrates.
eclampsia based on normal blood pressure and platelet
count. Ultrasound at that time revealed a single viable
fetus at 20 weeks gestation by biometric parameters
and normal amniotic fluid volume. Due to the
recurrence of her pulmonary haemorrhage a repeat
ultrasound was performed. Biometric measurements
suggested less than a week’s growth over the 3 weeks
since admission. In addition oligohydramnios was
noted. Although the clinical parameters of both lupus
exacerbation and superimposed pre-eclampsia overlap
so much, the diagnosis of superimposed pre-eclampsia
was considered. The lack of fetal growth and the
development of oligohydramnios were felt to be
incompatible with fetal survival. Therefore termina-
tion of pregnancy was offered and performed using
Misoprostol. Three days later her platelet count was
163 OOO/MM3 and her pulmonary status had improved
(Figure 4). The following day she was extubated after
10 days of mechanical ventilation. Oral cyclophos-
phamide was commenced. Over the next 2 days her
CXR returned to normal (Figure 5).
She continued to improve and was discharged from
hospital 7 weeks after her initial presentation on oral
cyclophosphamide and prednisone.
Discussion
Pulmonary haemorrhage is a rare but potentially
catastrophic complication of SLE. Earlier studies
Figure 2 Chest radiograph after extubation demonstrates radio graphic
improvement.
Figure 3 Chest radiograph following recurrence of pulmonary haemor-
rhage showing recurrence of diffuse infiltrates.
reported a mortality of 5~90% although a recent
study2 reported a 75% survival. Clinical features are
nonspecific, but diffuse alveolar infiltrates, hypox-
emia, dyspnoea and anaemia are characteristic.
Lupus pregnancy is, by definition, high risk
because of the increased fetal loss’ and incidence of
preterm delivery.¢’ The incidence of maternal lupus
flares during pregnancy is controversial and appears to
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Figure 4 Chest radiograph three days following termination of
pregnancy showing radiographic improvement.
be related to the severity of disease, socioeconomic
status and the predominance of immune complex
disease.8,9 Flares in the postpartum period are well
recognized.9°lo There is an increased risk of pre-
eclampsia, pregnancy induced hypertension and the
syndrome of hemolysis, elevated liver enzymes, low
platelets (HELLP) in lupus pregnancy.ll°’2 It can be
difficult to differentiate between a lupus flare and pre-
eclampsia and this differentiation may need to be
made in 25% of pregnancies.’ In many cases a clear
distinction cannot be made and it is possible that the
two conditions may coexist.&dquo; Lack of increase or a
reduction in the complement components C3 and C4
is more characteristic of a lupus flare&dquo; although low
levels of C4 have been reported in pregnant patients
with hypertension and proteinuria. 14
Low to modest dose corticosteroids and possibly
antimalarial drugs are the treatment of choice for
active lupus during pregnancy. Cleft lip and palate
have been described as side-effects of corticosteroids
in animals; however, these have not been reported in
humans. 15 Growth retardation has been reported at
higher doses. Azothioprine has been used extensively
in pregnancy in women with renal transplants with no
increase in birth defects&dquo; although this has not been
confirmed in all studies.&dquo; Î Cyclophosphamide is
clearly teratogenic in animals&dquo; and a malformation
rate of 22% has been described in humans
Consequently cyclophosphamide is used in pregnant
women with SLE only when life threatening immune
complex disease is refractory to other therapies.
Figure 5 Chest radiograph 5 days following termination of pregnancy
showing return to normal.
Due to the rarity of alveolar haemorrhage compli-
cating lupus, prospective, controlled trials evaluating
therapy have not been performed. The treatment of
choice is high dose steroids with or without
cyclophosphamide; plasmapheresis has been used
with anecdotal reports of success.’ 
I In randomized
controlled trials plasmapheresis plus prednisone and
cyclophosphamide were no more effective than
prednisone and cyclophosphamide alone for severe
lupus nephritis.’9 Consideration of plasmapheresis
should be reserved for patients with severe alveolar
haemorrhage refractory to corticosteroids and cyto-
toxic agents.
Our patient presents many of the dilemmas
discussed above. She developed a lupus flare during
the second trimester manifested as pulmonary hae-
morrhage, she had proteinuria without hypertension or
an active urinary sediment. Her alveolar haemorrhage
was refractory to treatment with steroids and
azothioprine necessitating the use of cyclophospha-
mide, with its associated risks, in association with
plasmapheresis. There was initial improvement with
this treatment; however, pulmonary haemorrhage
recurred despite the treatment with cyclophosphamide
and plasmapheresis. She subsequently developed an
elevated bilirubin and low platelets which along with
her refractory pulmonary alveolar haemorrhage re-
solved after delivery of the fetus.
This case demonstrates the clinical difficulty of
managing a lupus flare in pregnancy. In addition the
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clinical parameters used to make the diagnosis of
superimposed pre-eclampsia and HELLP syndrome
may not be specific enough to differentiate between
the two disease entities and may reflect a similar
pathophysiological pathway.
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